REFERENCES
- Abigail Alliance for Better Access to Developmental Drugs v Von Eschenbach. 2006. 445 F3rd 470 (D.C. Cir.).
- Bellamy, I. 2014. The illusions of “right to try” laws. Science-Based Medicine. March 6. Available at: http://www/sciencebasedmedicine.org/the-illusions-of-right-to-try-laws
- Bender, S., L. Flicker, and R. Rhodes. 2007. Access for the terminally ill to experimental medical innovations: A three-pronged threat. American Journal of Bioethics 7(10): 3–6.
- Caplan, A. 2007. Is it sound public policy to let the terminally ill access experimental medical innovations? American Journal of Bioethics 7(6): 1–3.
- Food and Drug Administration. 2009. 21 CFR Parts 312 and 316, Final Rule, Federal Register 74(155): 40900–40945.
- Leonard, E. W. 2009. Right to experimental treatment: FDA New approval, constitutional rights, and the public's health. Journal of Law, Medicine & Ethics 372(Summer): 2–12.
- Okie, S. 2006. Access before approval—A right to take experimental drugs. New England Journal of Medicine 355(August 3): 437–440.
- Ollove, M. 2014. Right-to-try for the terminally ill. USA Today. June 19. Available at: http://www.usatoday.com/story/news/nation/2014/06/19/stateline-fda
- Walker, M. J., W. A. Rogers, and V. Entwistle. 2014. Ethical justifications for access to unapproved medical interventions: An argument for (limited) patient obligations. American Journal of Bioethics 14(11): XX–XX.
- Wilenzick, M. 2007. Letter re Docket No 2006N-0061 dated February 14, Charging for investigational drugs. Available at: http://www.fda.gov/dockets/ecomments